Dimerix (ASX:DXB) agreed to acquire its US commercial licensing partner, Amicus Therapeutics, for about $4.8 billion in cash, according to a Friday filing with the Australian bourse.
The deal includes the company's commercial licensing contract, under which the company is eligible to receive $590 million in payments, the filing said.
The company's license deals outside the US remain unaffected, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments